Inclusion Criteria:

- Histologically confirmed PTCL NOS, angioimmunoblastic T-cell lymphoma, extranodal
NK/T-cell lymphoma nasal type, enteropathy- type T-cell lymphoma, hepatosplenic
T-cell lymphoma, ALCL (ALK-1 negative), or patients with ALK 1 expressing ALCL (ALK-1
positive) who have relapsed disease after ASCT

- Age ≥21 years

- Written informed consent

- Progressive disease following at least one systemic therapy or refractory to at least
one prior systemic therapy

- Measurable disease according to the IWC criteria and/or measurable bone marrow
disease by flow cytometry or morphology

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

- Absolute neutrophil count of ≥1000 × 10(9)cells/L

- Serum potassium ≥3.8 mmol/L and magnesium ≥0.85 mmol/L (electrolyte abnormalities can
be corrected with supplementation to meet inclusion criteria)

- Negative urine or serum pregnancy test on females of childbearing potential

- All females of childbearing potential and males must use an effective barrier method
of contraception during the treatment period and for at least 1 month thereafter.

Exclusion Criteria:

- Chemotherapy or immunotherapy within 3 weeks of study entry

- Concomitant use of any other anti-cancer therapy

- Concomitant use of any other investigational agent

- Any known cardiac abnormalities such as:

- Congenital long QT syndrome;

- QTcF interval >480 milliseconds (msec);

- A myocardial infarction within 12 months of study entry;

- Other significant ECG abnormalities including 2nd atrio-ventricular (AV) block
type II, 3rd degree AV block, or bradycardia (ventricular rate < 50 beats/
min).

- An ECG recorded at screening showing significant ST depression (ST depression of
≥2 mm, measured from isoelectric line to the ST segment at a point 60 msec at
the end of the QRS complex). If in any doubt, the patient should have a stress
imaging study and, if abnormal, angiography to define whether or not CAD is
present;

- Congestive heart failure (CHF) that meets New York Heart Association (NYHA)
Class II to IV definitions and/or ejection fraction <40% by MUGA scan or <50% by
echocardiogram and/or MRI;

- A known history of sustained ventricular tachycardia (VT), ventricular
fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently
addressed with an automatic implantable cardioverter defibrillator (AICD);

- Hypertrophic cardiomyopathy or restrictive cardiomyopathy from prior treatment
or other causes (if in doubt, see ejection fraction criteria above);

- Any cardiac arrhythmia requiring anti-arrhythmic medication;

- Serum potassium <3.8 mmol/L or serum magnesium <0.85 mmol/L (electrolyte
abnormalities can be corrected with supplementation to meet inclusion criteria)

- Concomitant use of drugs that may cause a prolongation of the QTcF

- Concomitant use of CYP3A4 inhibitors

- Impaired liver, renal or other organ function not caused by lymphoma, which will
interfere with the treatment schedule

- Concomitant use of warfarin due to a potential drug interaction

- Clinically significant active infection

- Known infection with human immunodeficiency virus (HIV)

- Patient has known clinically active hepatitis B or C

- Previous extensive radiotherapy involving ≥30% of bone marrow (e.g., whole pelvis,
half spine), excluding patients who have had total body irradiation as part of a
conditioning regimen for stem cell transplant

- Major surgery within 2 weeks of study entry

- Peripheral neuropathy or neuropathic pain of Grade 2 or worse

- Platelet count <50 × 109 cells/L or platelet count <30 × 109 cells/L if bone marrow
disease involvement is documented

- Serum creatinine >2.0 × ULN

- Patients who are pregnant or breast-feeding

- Patient has known hypersensitivity to any components of bortezomib (such as boron,
mannitol), or panobinostat